198 related articles for article (PubMed ID: 30945556)
21. Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Ganesan R; Kolumam GA; Lin SJ; Xie MH; Santell L; Wu TD; Lazarus RA; Chaudhuri A; Kirchhofer D
Mol Cancer Res; 2011 Sep; 9(9):1175-86. PubMed ID: 21875933
[TBL] [Abstract][Full Text] [Related]
22. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
23. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
24. The type II transmembrane serine protease, matriptase-2: Possible links to cancer?
Sanders AJ; Webb SL; Parr C; Mason MD; Jiang WG
Anticancer Agents Med Chem; 2010 Jan; 10(1):64-9. PubMed ID: 20015002
[TBL] [Abstract][Full Text] [Related]
25. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
26. Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2.
Maurer E; Gütschow M; Stirnberg M
Biochem J; 2013 Mar; 450(3):583-93. PubMed ID: 23293962
[TBL] [Abstract][Full Text] [Related]
27. Structure-Based Design of High-Affinity and Selective Peptidomimetic Hepsin Inhibitors.
Knaff PM; Müller P; Kersten C; Wettstein L; Münch J; Landfester K; Mailänder V
Biomacromolecules; 2022 Jun; 23(6):2236-2242. PubMed ID: 35593713
[TBL] [Abstract][Full Text] [Related]
28. Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
Häußler D; Mangold M; Furtmann N; Braune A; Blaut M; Bajorath J; Stirnberg M; Gütschow M
Chemistry; 2016 Jun; 22(25):8525-35. PubMed ID: 27214780
[TBL] [Abstract][Full Text] [Related]
29. Identification of the first low-molecular-weight inhibitors of matriptase-2.
Sisay MT; Steinmetzer T; Stirnberg M; Maurer E; Hammami M; Bajorath J; Gütschow M
J Med Chem; 2010 Aug; 53(15):5523-35. PubMed ID: 20684597
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
[TBL] [Abstract][Full Text] [Related]
32. Active site mapping of trypsin, thrombin and matriptase-2 by sulfamoyl benzamidines.
Dosa S; Stirnberg M; Lülsdorff V; Häußler D; Maurer E; Gütschow M
Bioorg Med Chem; 2012 Nov; 20(21):6489-505. PubMed ID: 23026080
[TBL] [Abstract][Full Text] [Related]
33. Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
Damalanka VC; Voss JJLP; Mahoney MW; Primeau T; Li S; Klampfer L; Janetka JW
J Med Chem; 2021 Dec; 64(24):18158-18174. PubMed ID: 34902246
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of the catalytic domain of DESC1, a new member of the type II transmembrane serine proteinase family.
Kyrieleis OJ; Huber R; Ong E; Oehler R; Hunter M; Madison EL; Jacob U
FEBS J; 2007 Apr; 274(8):2148-60. PubMed ID: 17388811
[TBL] [Abstract][Full Text] [Related]
35. Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1.
Yuan C; Chen L; Meehan EJ; Daly N; Craik DJ; Huang M; Ngo JC
BMC Struct Biol; 2011 Jun; 11():30. PubMed ID: 21693064
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein.
Kawaguchi M; Orikawa H; Baba T; Fukushima T; Kataoka H
FEBS J; 2009 Jul; 276(13):3481-90. PubMed ID: 19456860
[TBL] [Abstract][Full Text] [Related]
37. A Bisbenzamidine Phosphonate as a Janus-faced Inhibitor for Trypsin-like Serine Proteases.
Häußler D; Scheidt T; Stirnberg M; Steinmetzer T; Gütschow M
ChemMedChem; 2015 Oct; 10(10):1641-6. PubMed ID: 26306030
[TBL] [Abstract][Full Text] [Related]
38. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
Hum Cell; 2016 Jan; 29(1):22-9. PubMed ID: 26250899
[TBL] [Abstract][Full Text] [Related]
39. Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide libraries.
Barré O; Dufour A; Eckhard U; Kappelhoff R; Béliveau F; Leduc R; Overall CM
PLoS One; 2014; 9(9):e105984. PubMed ID: 25211023
[TBL] [Abstract][Full Text] [Related]
40. Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases.
Furtmann N; Häußler D; Scheidt T; Stirnberg M; Steinmetzer T; Bajorath J; Gütschow M
Chemistry; 2016 Jan; 22(2):610-25. PubMed ID: 26625703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
